GR1006879B - Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων - Google Patents

Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων

Info

Publication number
GR1006879B
GR1006879B GR20050100466A GR20050100466A GR1006879B GR 1006879 B GR1006879 B GR 1006879B GR 20050100466 A GR20050100466 A GR 20050100466A GR 20050100466 A GR20050100466 A GR 20050100466A GR 1006879 B GR1006879 B GR 1006879B
Authority
GR
Greece
Prior art keywords
reductase inhibitor
preperation
pharmaceutical composition
composition containing
coa reductase
Prior art date
Application number
GR20050100466A
Other languages
English (en)
Other versions
GR20050100466A (el
Inventor
Ευαγγελος Καραβας
Ευθυμιος Κουτρης
Δημητριος Μπικιαρης
Original Assignee
"Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., filed Critical "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε.,
Priority to GR20050100466A priority Critical patent/GR1006879B/el
Priority to EP06779673A priority patent/EP1924258A1/en
Priority to PCT/GR2006/000046 priority patent/WO2007031801A1/en
Priority to US12/063,222 priority patent/US20080213356A1/en
Priority to CA002612769A priority patent/CA2612769A1/en
Publication of GR20050100466A publication Critical patent/GR20050100466A/el
Publication of GR1006879B publication Critical patent/GR1006879B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τη σύνθεση στέρεων δοσολογικών μορφών που αποτελούνται από θεραπευτικά αποτελεσματική ποσότητα αναστολέα αναγωγάσης HMG-CoA και ιδιαιτέρων Fluvastatin ή Atorvastatinή αλάτων αυτών σε συνδυασμό με πολυμερές οργανικής ένωσης πυριτίου όπως Dimethicon και με τη μέθοδο παρασκευής αυτών μέσω άμεσης συμπίεσης.
GR20050100466A 2005-09-14 2005-09-14 Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων GR1006879B (el)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GR20050100466A GR1006879B (el) 2005-09-14 2005-09-14 Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
EP06779673A EP1924258A1 (en) 2005-09-14 2006-09-13 IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF
PCT/GR2006/000046 WO2007031801A1 (en) 2005-09-14 2006-09-13 IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF
US12/063,222 US20080213356A1 (en) 2005-09-14 2006-09-13 Pharmaceutical Composition Containing Hmg-Coa Reductase Inhibitor And Method For The Preparation Thereof
CA002612769A CA2612769A1 (en) 2005-09-14 2006-09-13 Improved pharmaceutical composition containing hmg-coa reductase inhibitor and method for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20050100466A GR1006879B (el) 2005-09-14 2005-09-14 Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων

Publications (2)

Publication Number Publication Date
GR20050100466A GR20050100466A (el) 2007-04-25
GR1006879B true GR1006879B (el) 2010-07-13

Family

ID=38109581

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20050100466A GR1006879B (el) 2005-09-14 2005-09-14 Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων

Country Status (5)

Country Link
US (1) US20080213356A1 (el)
EP (1) EP1924258A1 (el)
CA (1) CA2612769A1 (el)
GR (1) GR1006879B (el)
WO (1) WO2007031801A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000286A1 (en) * 2007-06-25 2008-12-31 Parmatheen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
TR200800634A2 (tr) * 2008-01-30 2009-02-23 Takka Sevgi̇ Uzatılmış salım sağlayan fluvastatin tablet.
EP2464428A2 (en) * 2009-08-13 2012-06-20 Dow Corning Corporation Granulated dry cleanser for the care of keratinous substrates
GR1008819B (el) * 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
AU2018255510B2 (en) * 2017-04-20 2024-05-30 Cubopharm Pty Ltd Liquid crystalline dosage form for administering a statin
AU2018255718A1 (en) 2017-04-20 2019-12-05 Zeenar Enterprises Pty Ltd Fast disintegrating tablet
US20210145730A1 (en) * 2017-04-20 2021-05-20 Zeenar Enterprises Pty Ltd Process for preparing an oral disintegrating dosage form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
US6967218B2 (en) * 2002-01-11 2005-11-22 Biovail Laboratories, Inc. Pravastatin pharmaceutical formulations and methods of their use
JP2006503023A (ja) * 2002-09-03 2006-01-26 バイオヴェイル ラボラトリーズ インコーポレイテッド スタチン薬物の放出調節ための医薬品製剤および方法
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent

Also Published As

Publication number Publication date
CA2612769A1 (en) 2007-03-22
US20080213356A1 (en) 2008-09-04
EP1924258A1 (en) 2008-05-28
GR20050100466A (el) 2007-04-25
WO2007031801A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2008062476A3 (en) Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2006102674A3 (en) Diphenylheterocycle cholesterol absorption inhibitors
WO2009010787A3 (en) Stable pharmaceutical compositions comprising one or more hmg-coa reductase inhibitors
NO20076191L (no) Magnesiumsalter av HMG-COA reduktaseinhibitorer
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
TW200744583A (en) Statin stabilizing dosage formulations
SG141430A1 (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
WO2008057464A3 (en) Compositions and methods for improving the bioavailability of liothyronine
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
WO2009000286A8 (en) Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
TW200714280A (en) Novel method of treating hyperlipidemia
WO2006008091A3 (en) Oxidative degradation products of atorvastatin calcium
CY1108846T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει αναστολεα ace και μεθοδος για την παρασκευη της
EP1871396A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS WITH AN HMG COA REDUCTASE INHIBITOR
MX2007007283A (es) Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal.
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
WO2008001311A3 (en) Pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate
WO2006103119A3 (en) Tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees

Effective date: 20150403